Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Esperion Therapeutics Q2 EPS $(0.02) Beats $(0.14) Estimate, Sales $82.385M Beat $63.142M Estimate

Author: Benzinga Newsdesk | August 05, 2025 06:01am
Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.14) by 85.51 percent. This is a 93.94 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $82.385 million which beat the analyst consensus estimate of $63.142 million by 30.48 percent. This is a 11.58 percent increase over sales of $73.834 million the same period last year.

Posted In: ESPR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist